BIO Wants 14 Years Of Data Exclusivity For Biosimilars; Will Waxman Buy It?

Biotechnology Industry Organization CEO Jim Greenwood has drawn a line in the sand over follow-on biologics: he will not accept less than 14 years of data exclusivity for innovator products. And he says he has the data to back it up